A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort

This study will evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses (SAD) and multiple ascending doses (MAD) of AZD4248 administered as an oral solution and intravenous (IV) infusion. Additionally, the study investigates the non-interventional feasibility of home measurement of serum creatinine in participants with diabetic kidney disease (DKD).

NCT Number	NCT07024823
Lead Sponsor	AstraZeneca Collaborators: Parexel
Conditions	Chronic Kidney Disease
Enrollment	124 participants
Start Date	2025-06-09
Primary Completion	2026-12-25 (estimated)
Study Completion	2026-12-25 (estimated)
Updated on ClinicalTrials.gov	2026-08-12